LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・Anika Therapeutics Inc

Anika Therapeutics Inc

Open

SectorGezondheidszorg

14.84 -3.39

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.31

Max

15.42

Belangrijke statistieken
By Trading Economics
Inkomsten	-5.3M -5.1M
Verkoop	-1M 30M
EPS	0.27
Winstmarge	-17.074
Werknemers	235
EBITDA	-6.3M -4.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+18.24% upside

Dividenden
By Dow Jones
Volgende Winsten	29 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-35M 193M
Vorige openingsprijs	18.23
Vorige sluitingsprijs	14.84

Nieuwssentiment

By Acuity

50%

171 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

14.51 / 14.745 Steun & Weerstand

Anika Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mei 2026, 22:27 UTC

Acquisities, Fusies, Overnames

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mei 2026, 22:12 UTC

Winsten

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mei 2026, 21:52 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs

15 mei 2026, 00:00 UTC

Winsten

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mei 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mei 2026, 23:56 UTC

Marktinformatie

Gold Prices Rise on Strong Demand -- Market Talk

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mei 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mei 2026, 23:47 UTC

Winsten

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mei 2026, 23:47 UTC

Winsten

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mei 2026, 23:28 UTC

Marktinformatie

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mei 2026, 23:00 UTC

Marktinformatie

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 mei 2026, 22:35 UTC

Marktinformatie

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mei 2026, 22:11 UTC

Acquisities, Fusies, Overnames

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mei 2026, 22:06 UTC

Marktinformatie

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mei 2026, 22:00 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q EPS 18c >NU

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q Rev $4.97B >NU

Peer Vergelijking

Prijswijziging

Anika Therapeutics Inc Prognose

Koersdoel

By TipRanks

18.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 17.5 USD 18.24%

Hoogste 18 USD

Laagste 17 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Anika Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Anika Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

14.51 / 14.745Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

171 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.